Jianlong Su

Jan 10, 2025 | onlinelibrary.wiley.com | Yang Wang |Guangzhe Li |Jianlong Su |Yiming Liu

Conflict of Interest The authors declare no conflict of interest. Supporting Information Filename Description smll202406839-sup-0001-SuppMat.docx17 MB Supporting Information References 1, , , , , , , , , , , , Neuro.Oncol. 2014, 16, 896. 2a) , , , , , , , , , , , , , , , , , , , N. Engl. J. Med. 2005, 352, 987; b) , , , J. Exp. Clin. Cancer Res. 2022, 41, 142. 3a) , , , , , , Ann. Oncol. 2014, 25, iii93; b) , , , , , , , , , , , , , , , , , , , , , BMC Cancer 2019, 19, 198.

Feb 2, 2024 | onlinelibrary.wiley.com | Yang Wang |Guangzhe Li |Jianlong Su |Yiming Liu

1 Introduction Despite the paramount success, cancer immunotherapy maintains limited clinical benefits for patients with solid tumors owing to their immunosuppressive microenvironment.[1] Solid tumors with poor immunogenicity are characterized by the lack of the host's pre-existing anti-tumor immunity and T lymphocytes infiltration, namely immunological “cold” tumors, which readily escape from immune clearance as well as induce progression and metastasis by modifying their local...